Skip to main content

Closed

HQL: Tekla Life Sciences Investors Stock Analysis | finqOS

Financial Services · Asset Management

Loading chart data...

Current StateBalance holding

The verdict

Good business

Strong

Operating margin331.9%

ROIC35.2%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio2.58×

Valuation

Unrated

P/E ratio2.8×

Dividend yield10.7%

Tekla Life Sciences Investors

HQLNew York Stock Exchange·USD·Closed

Tekla Life Sciences Investors

HQLNew York Stock Exchange·USD·Closed

$19.10

−1.75%

$19.10

−$0.34 (1.75%)

52W Range

73thpctl

Volume

1.09×avg

Mkt Cap

580.79MUSD

P/E

2.8TTM

Div Yield

10.68%ann

52W Range

73thpctl

Volume

1.09×avg

Market Cap

580.79MUSD

P/E Ratio

2.8TTM

Div Yield

10.68%ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings